RBC Capital Cuts PT on Legend Biotech Corporation (LEGN) to $62 From $66 – Here’s Why
WhatRBC Capital Markets has downgraded Legend Biotech Corporation's stock price target to $62 from $66, citing a reevaluation of the company's growth prospects.
WhyThe downgrade is attributed to concerns over the company's ability to sustain its growth momentum, with analysts questioning the long-term viability of its current business model.
SignalThis move by RBC Capital Markets serves as a warning sign for investors, indicating potential risks and challenges ahead for Legend Biotech Corporation.
TargetInvestors who had previously set their sights on the $66 price target may need to reassess their expectations, with the new target of $62 offering a more conservative outlook.
RiskThe downgrade by RBC Capital Markets increases the risk for Legend Biotech Corporation, as investors may become more cautious and hesitant to invest in the company, potentially impacting its stock price and overall performance.